110 related articles for article (PubMed ID: 15543569)
1. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.
Rommel O; Dillner J; Fligge C; Bergsdorf C; Wang X; Selinka HC; Sapp M
J Med Virol; 2005 Jan; 75(1):114-21. PubMed ID: 15543569
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
4. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
5. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.
Joyce JG; Tung JS; Przysiecki CT; Cook JC; Lehman ED; Sands JA; Jansen KU; Keller PM
J Biol Chem; 1999 Feb; 274(9):5810-22. PubMed ID: 10026203
[TBL] [Abstract][Full Text] [Related]
6. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
7. Further evidence that papillomavirus capsids exist in two distinct conformations.
Selinka HC; Giroglou T; Nowak T; Christensen ND; Sapp M
J Virol; 2003 Dec; 77(24):12961-7. PubMed ID: 14645552
[TBL] [Abstract][Full Text] [Related]
8. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
9. Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.
Wang X; Sapp M; Christensen ND; Dillner J
J Gen Virol; 2005 Jan; 86(Pt 1):65-73. PubMed ID: 15604432
[TBL] [Abstract][Full Text] [Related]
10. Equine papillomavirus type 1: complete nucleotide sequence and characterization of recombinant virus-like particles composed of the EcPV-1 L1 major capsid protein.
Ghim SJ; Rector A; Delius H; Sundberg JP; Jenson AB; Van Ranst M
Biochem Biophys Res Commun; 2004 Nov; 324(3):1108-15. PubMed ID: 15485669
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
[TBL] [Abstract][Full Text] [Related]
12. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.
Christensen ND; Höpfl R; DiAngelo SL; Cladel NM; Patrick SD; Welsh PA; Budgeon LR; Reed CA; Kreider JW
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2271-6. PubMed ID: 7521393
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism.
Mistry N; Wibom C; Evander M
Virol J; 2008 Oct; 5():118. PubMed ID: 18854037
[TBL] [Abstract][Full Text] [Related]
14. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.
Cook JC; Joyce JG; George HA; Schultz LD; Hurni WM; Jansen KU; Hepler RW; Ip C; Lowe RS; Keller PM; Lehman ED
Protein Expr Purif; 1999 Dec; 17(3):477-84. PubMed ID: 10600468
[TBL] [Abstract][Full Text] [Related]
15. Insights into the role and function of L2, the minor capsid protein of papillomaviruses.
Pereira R; Hitzeroth II; Rybicki EP
Arch Virol; 2009; 154(2):187-97. PubMed ID: 19169853
[TBL] [Abstract][Full Text] [Related]
16. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33.
Fligge C; Giroglou T; Streeck RE; Sapp M
Virology; 2001 May; 283(2):353-7. PubMed ID: 11336560
[TBL] [Abstract][Full Text] [Related]
17. Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity.
Bousarghin L; Touzé A; Yvonnet B; Coursaget P
J Med Virol; 2004 Jul; 73(3):474-80. PubMed ID: 15170645
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
19. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.
McCarthy MP; White WI; Palmer-Hill F; Koenig S; Suzich JA
J Virol; 1998 Jan; 72(1):32-41. PubMed ID: 9420197
[TBL] [Abstract][Full Text] [Related]
20. Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay.
Ko YJ; Choi KS; Nah JJ; Paton DJ; Oem JK; Wilsden G; Kang SY; Jo NI; Lee JH; Kim JH; Lee HW; Park JM
Clin Diagn Lab Immunol; 2005 Aug; 12(8):922-9. PubMed ID: 16085909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
